Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Director comp.
Consulting agrmnt
Director departure
Quarterly results
Appointed director
CC transcript
Inv. presentation

MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/19/2019 RW Form RW - Registration Withdrawal Request:
05/09/2019 SC 13G/A Opko Health, Inc. reports a 5% stake in MABVAX THERAPEUTICS HOLDINGS, INC.
04/24/2019 10-Q/A Quarterly Report for the period ended September 30, 2018 [amend]
03/29/2019 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
03/29/2019 10-Q/A Quarterly Report for the period ended September 30, 2018 [amend]
03/25/2019 8-K Bankruptcy or Receivership, Financial Statements and Exhibits
01/04/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MabVax Therapeutics and Oncotelic Enter into Merger Discussions Divestiture of Selected MabVax Assets Managed by Objective Capital Will Continue SAN DIEGO – MabVax Therapeutics Holdings, Inc. , a clinical-stage immuno-oncology drug development company with a fully human antibody discovery platform focused on the clinical development of products to address unmet medical needs in the treatment of cancer and pancreatitis, today announced that it has entered into discussions to merge with Oncotelic, Inc., a privately held cancer immunotherapy company. Oncotelic is developing a unique TGF- antisense therapy which has demonstrated the ability to break immune tolerance in mid-stage clinical trials for the treatment of glioblastoma and pancreatic cancer. Based on terms of a non-binding letter of i..."
11/20/2018 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
11/20/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Equity Purchase Agreement with Triton Funds LP",
"Registration Rights Agreement",
"Share Donation Agreement"
11/13/2018 10-Q Quarterly Report for the period ended September 30, 2018
10/22/2018 CT ORDER Form CT ORDER - Confidential treatment order:
10/16/2018 8-K Quarterly results
10/15/2018 10-Q Quarterly Report for the period ended June 30, 2018
10/15/2018 10-Q Quarterly Report for the period ended March 31, 2018
10/15/2018 10-K/A Annual Report for the period ended December 31, 2017 [amend]
09/27/2018 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
08/06/2018 SC 13G Honig Barry C reports a 5% stake in MABVAX THERAPEUTICS HOLDINGS, INC.
08/02/2018 GN DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against MabVax Therapeutics Holdings (MBVX) & Lead Plaintiff Deadline – August 3, 2018
07/26/2018 GN FINAL DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX) To Contact The Firm
07/25/2018 SC 13D/A Stetson John reports a 5% stake in MABVAX THERAPEUTICS HOLDINGS, INC.
07/12/2018 GN Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MabVax Therapuetics Holdings, Flex Pharma, Inc. and Ormat Technologies, Inc. and Encourages Investors to Contact the Firm
07/09/2018 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MabVax Therapeutics and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers"
07/06/2018 GN MBVX LOSS ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against MabVax Therapeutics Holdings, Inc. – MBVX
07/05/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "MabVax Therapeutics Receives Nasdaq Delist Determination San Diego, CA, July 5, 2018 – MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that as a result of the Company’s decision not to submit a plan to regain compliance with Nasdaq’s filing requirement, which decision was announced by the Company in a press release on July 2, 2018, on that same date, the Listing Qualifications Staff of The Nasdaq Stock Market LLC notified the Company of its determination to delist the Company’s securities from Nasdaq. The Staff indicated that the determination was based upon the Company’s non-compliance wi..."
07/03/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "ADDITIONAL EXHIBITS"
07/02/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "MabVax Therapeutics Decides Not to Submit Plan to Regain Compliance with Nasdaq Listing Standards"
06/29/2018 GN MabVax Shareholder Class Action: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against MabVax Therapeutics Holdings, Inc. - MBVX
06/29/2018 GN LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In MabVax Therapeutics Holdings, Inc. To Contact The Firm
06/29/2018 GN SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against MabVax Therapeutics Holdings (MBVX) & Lead Plaintiff Deadline – August 3, 2018
06/28/2018 GN Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against MabVax Therapeutics Holdings, Inc. (MBVX) and Encourages Investors to Contact the Firm
06/26/2018 GN SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
06/15/2018 GN SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against MabVax Therapeutics Holdings (MBVX) & Lead Plaintiff Deadline – August 3, 2018
06/06/2018 GN SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX) To Contact Brower Piven Before The Lead Plaintiff Deadline
06/05/2018 GN Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against MabVax Therapeutics Holdings, Inc. (MBVX)
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy